US2008057032A1PendingUtilityA1

Combination therapy (temozolomide and alpha-ifn) for advanced cancer

62
Individually held — no corporate assignee on recordPriority: Oct 4, 1995Filed: Nov 5, 2007Published: Mar 6, 2008
Est. expiryOct 4, 2015(expired)· nominal 20-yr term from priority
Inventors:Margaret Dugan
A61K 9/4858A61P 35/00A61K 38/212A61K 45/06A61K 31/495
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

There is disclosed a method for treating advanced cancer in patients in need of such treating. Temozolomide and alpha interferon are administered in combination in amounts sufficient to achieve a clinical response.

Claims

exact text as granted — not AI-modified
1 . A method for treating advanced cancer in patients in need of 5 such treating comprising administering temozolomide and alpha interferon in amounts sufficient to achieve a clinical response.  
     
     
         2 . The method of  claim 1  wherein the amount of temozolomide administered is from 50 to 400 mg per m 2  of the patient's body surface area per 10 day for a period of from 2 to 10 days and the amount of alpha interferon administered is from 1 million to 25 million IU per m 2  of the patient's body surface area administered intraveneously or subcutaneously 1 to 7 times per week.  
     
     
         3 . The method of  claim 2  wherein beginning 28 to 42 days after the first day of the temozolomide administration period, the temozolomide administrations are repeated.  
     
     
         4 . The method of  claim 3  wherein the alpha interferon administered is interferon alpha 2b.  
     
     
         5 . The method of  claim 2  wherein the amount of temozolomide administered is from 75 to 300 mg per m 2  of the patient's body surface area per day for a period of from 3 to 8 days and the amount of alpha interferon administered is from 5 million to 15 million IU per m 2  of the patient's body surface area administered intraveneously or subcutaneously.  
     
     
         6 . The method of  claim 5  wherein beginning about 28 to 35 days after the first day of the temozolomide administration period, the temozolomide administrations are repeated.  
     
     
         7 . The method of  claim 6  wherein the alpha interferon administered is interferon alpha 2b.  
     
     
         8 . The method of  claim 5  wherein the amount of temozolomide administered is from 100 to 200 mg per m 2  of the patient's body surface area per day for a period of 5 days and the amount of alpha interferon administered is from 7.5 million to 12.5 million IU per m 2  of the patients body surface area administered intraveneously or subcutaneously.  
     
     
         9 . The method of  claim 8  wherein beginning 28 days after the first day of the temozolomide administration period, the temozolomide administrations are repeated.  
     
     
         10 . The method of  claim 9  wherein the alpha interferon administered is interferon alpha 2b.  
     
     
         11 . The method of  claim 1  wherein the temozolomide is administered orally after the patient has fasted from food and liquids other than water for 4 hours before temozolomide administration and for 2 hours after temozolomide administration.  
     
     
         12 . The method of  claim 2  wherein the temozolomide is administered orally after the patient has fasted from food and liquids other than water for 4 hours before temozolomide administration and for 2 hours after temozolomide administration.  
     
     
         13 . The method of  claim 3  wherein the temozolomide is administered orally after the patient has fasted from food and liquids other than water for 4 hours before temozolomide administration and for 2 hours after temozolomide administration.  
     
     
         14 . The method of  claim 4  wherein the temozolomide is administered orally after the patient has fasted from food and liquids other than water for 4 hours before temozolomide administration and for 2 hours after temozolomide administration.  
     
     
         15 . The method of  claim 5  wherein the temozolomide is administered orally after the patient has fasted from food and liquids other than water for 4 hours before temozolomide administration and for 2 hours after temozolomide administration.  
     
     
         16 . The method of  claim 6  wherein the temozolomide is administered orally after the patient has fasted from food and liquids other than water for 4 hours before temozolomide administration and for 2 hours after temozolomide administration.  
     
     
         17 . The method of  claim 7  wherein the temozolomide is administered orally after the patient has fasted from food and liquids other than water for 4 hours before temozolomide administration and for 2 hours after temozolomide administration.  
     
     
         18 . The method of  claim 8  wherein the temozolomide is administered orally after the patient has fasted from food and liquids other than water for 4 hours before temozolomide administration and for 2 hours after temozolomide administration.  
     
     
         19 . The method of  claim 9  wherein the temozolomide is administered orally after the patient has fasted from food and liquids other than water for 4 hours before temozolomide administration and for 2 hours after temozolomide administration.  
     
     
         20 . The method of  claim 10  wherein the temozolomide is administered orally after the patient has fasted from food and liquids other than water for 4 hours before temozolomide administration and for 2 hours after temozolomide administration.  
     
     
         21 . The method of  claim 1  wherein the temozolomide is administered orally for a period of from 6 days to six weeks.

Join the waitlist — get patent alerts

Track US2008057032A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.